報價延遲最少15分鐘:2024/12/24 12:56 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.68 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.40/0.41
|
|
企業價值
267.99M
|
| 資產負債 |
|
每股賬面淨值
1.47
|
| 現金流量 |
|
現金流量率
0.19
|
| 損益表 |
|
收益
14.80M
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:56 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others. |